Researchers evaluate botanicals' impact on menopause
This article was originally published in The Tan Sheet
A $7.4 million, five-year grant by the National Institutes of Health supports the University of Illinois at Chicago College of Pharmacy's research into the palliative effects of botanical dietary supplements, including black cohosh, licorice and hops, on menopausal symptoms. Norman Farnsworth, director of UIC's Program for Collaborative Research in Pharmaceutical Sciences, will lead the research to assess how multi-component mixtures work together, how they are absorbed, distributed and eliminated by the body and how they affect chemical and physical processes within the body, the college announces Sept. 1. Researchers also will study how the mixtures interact with drugs and impact women's estrogenic hormones. The grant is the third under the Botanical Research Centers Program, which was started after NIH's Office of Dietary Supplements received funding in 1999 to develop a botanicals initiative
You may also be interested in...
The University of Missouri launches a national center to lead interdisciplinary and collaborative research on botanical dietary supplements with a $7.6 million, five-year National Institutes of Health grant. The university's Center for Botanical Interaction Studies will focus on the capabilities of garlic, elderberry, soy and other botanicals to help prevent stroke and prostate cancer and improve resistance to infectious diseases. Grace Sun, professor of biochemistry, pathology and anatomical sciences and a member of the university's Interdisciplinary Neuroscience Program, will lead a team of more than 20 scientists in studying how the botanicals use antioxidant properties to protect people from disease. The grant is from the NIH Office of Dietary Supplements' Botanical Research Centers Program (1"The Tan Sheet" Sept. 6, 2010, In Brief)
ABHI’s Phil Brown believes the future of UK device regulation will be innovation-friendly and patient-responsive system – but doesn’t expect easy alignment with the EU. See what he had to say.
Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.